IRVINE, Calif.—Konan Medical USA
has acquired objectiveFIELD, an FDA-cleared objective perimeter, from the Australian National University (ANU). The purchase price was not announced. The device, which Konan said is designed to “assess the human visual field in a completely objective and non-contact manner,” does not require manual input from the patient. Using a patented multi-focal pupil objective perimetry method (mfPOP), objectiveFIELD tests both eyes simultaneously in minutes, according to Konan. It includes novel features licensed from Seeing Machines
, and is the brainchild of noted researcher Ted Maddess, PhD, and his team “The Maddess Group—Diagnostics for Eye Diseases,” at the John Curtin School of Medical Research in Australia.
The intellectual property acquired by Konan includes 15 issued patents in nine countries, six patents in process, and clinical data to support a wide range of important diagnostic indications.
objectiveFIELD has been clinically researched in Australia over more than a 12-year period with more than 16,000 examinations across normal, glaucoma, macular degeneration, diabetic retinopathy, multiple sclerosis, epilepsy, migraine, concussion, and other neuro-vision conditions. Konan noted that objectiveFIELD is not cleared for specific diagnosis of these conditions.
Konan is planning to debut the objectiveFIELD at the American Academy of Ophthalmology Annual Meeting in Chicago from Oct. 26 to 30, 2018. The company will also showcase it at the American Academy of Optometry in San Antonio, Texas, Nov. 7 to 9, 2018.